{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:33:00Z","timestamp":1791567180237,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40262-023-01261-3","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T18:02:12Z","timestamp":1686938532000},"page":"1141-1155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Activity of Members of the UDP-Glucuronosyltransferase Subfamilies UGT1A and UGT2B is Impaired in Patients with Liver Cirrhosis"],"prefix":"10.1007","volume":"62","clinical-trial-number":[{"clinical-trial-number":"nct03337945","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Urs","family":"Duthaler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustos C.","family":"Ozbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Parrott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8347-4145","authenticated-orcid":false,"given":"Stephan","family":"Kr\u00e4henb\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"issue":"6","key":"1261_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2165\/00002018-200528060-00005","volume":"28","author":"F Delco","year":"2005","unstructured":"Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S. Dose adjustment in patients with liver disease. Drug Saf. 2005;28(6):529\u201345.","journal-title":"Drug Saf"},{"issue":"3","key":"1261_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","volume":"49","author":"TN Johnson","year":"2010","unstructured":"Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49(3):189\u2013206.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1261_CR3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00228-013-1502-z","volume":"69","author":"CC Franz","year":"2013","unstructured":"Franz CC, Hildbrand C, Born C, Egger S, R\u00e4tz Bravo AE, Kr\u00e4henb\u00fchl S. Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations. Eur J Clin Pharmacol. 2013;69(8):1565\u201373.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1261_CR4","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","volume":"45","author":"A Rowland","year":"2013","unstructured":"Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 2013;45(6):1121\u201332.","journal-title":"Int J Biochem Cell Biol"},{"key":"1261_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107689","volume":"218","author":"JO Miners","year":"2021","unstructured":"Miners JO, Rowland A, Novak JJ, Lapham K, Goosen TC. Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping. Pharmacol Ther. 2021;218: 107689.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"1261_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/03602532.2017.1293682","volume":"49","author":"G Yang","year":"2017","unstructured":"Yang G, Ge S, Singh R, Basu S, Shatzer K, Zen M, et al. Glucuronidation: driving factors and their impact on glucuronide disposition. Drug Metab Rev. 2017;49(2):105\u201338.","journal-title":"Drug Metab Rev"},{"issue":"4","key":"1261_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/cpt1978244411","volume":"24","author":"JW Kraus","year":"1978","unstructured":"Kraus JW, Desmond PV, Marshall JP, Johnson RF, Schenker S, Wilkinson GR. Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther. 1978;24(4):411\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1261_CR8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.7326\/0003-4819-84-4-420","volume":"84","author":"HJ Shull","year":"1976","unstructured":"Shull HJ, Wilkinson GR, Johnson R, Schenker S. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med. 1976;84(4):420\u20135.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1261_CR9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/hep.1840030322","volume":"3","author":"F Witassek","year":"1983","unstructured":"Witassek F, Bircher J, Huguenin P, Preisig R. Abnormal glucuronidation of zomepirac in patients with cirrhosis of the liver. Hepatology. 1983;3(3):415\u201322.","journal-title":"Hepatology"},{"issue":"5","key":"1261_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/BF00558076","volume":"36","author":"B Crotty","year":"1989","unstructured":"Crotty B, Watson KJ, Desmond PV, Mashford ML, Wood LJ, Colman J, et al. Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol. 1989;36(5):501\u20136.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1261_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1365-2125.1990.tb03638.x","volume":"29","author":"J Hasselstr\u00f6m","year":"1990","unstructured":"Hasselstr\u00f6m J, Eriksson S, Persson A, Rane A, Svensson JO, S\u00e4we J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol. 1990;29(3):289\u201397.","journal-title":"Br J Clin Pharmacol"},{"key":"1261_CR12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.0954-6820.1979.tb00728.x","volume":"624","author":"PB Andreasen","year":"1979","unstructured":"Andreasen PB, Hutters L. Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. Acta Med Scand Suppl. 1979;624:99\u2013105.","journal-title":"Acta Med Scand Suppl"},{"issue":"4","key":"1261_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/S0016-5085(99)70075-2","volume":"116","author":"PR Froomes","year":"1999","unstructured":"Froomes PR, Morgan DJ, Smallwood RA, Angus PW. Comparative effects of oxygen supplementation on theophylline and acetaminophen clearance in human cirrhosis. Gastroenterology. 1999;116(4):915\u201320.","journal-title":"Gastroenterology"},{"issue":"1","key":"1261_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-2036.2004.02022.x","volume":"20","author":"P Zapater","year":"2004","unstructured":"Zapater P, Lasso de la Vega MC, Horga JF, Such J, Frances R, Esteban A, et al. Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. Aliment Pharmacol Ther. 2004;20(1):29\u201336.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1261_CR15","first-page":"475","volume":"264","author":"C Jin","year":"1993","unstructured":"Jin C, Miners JO, Lillywhite KJ, Mackenzie PI. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther. 1993;264(1):475\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"1261_CR16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/FPC.0000000000000150","volume":"25","author":"LL Mazaleuskaya","year":"2015","unstructured":"Mazaleuskaya LL, Sangkuhl K, Thorn CF, FitzGerald GA, Altman RB, Klein TE. PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015;25(8):416\u201326.","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"1261_CR17","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40262-022-01119-0","volume":"61","author":"U Duthaler","year":"2022","unstructured":"Duthaler U, Bachmann F, Suenderhauf C, Grandinetti T, Pfefferkorn F, Haschke M, et al. Liver cirrhosis affects the pharmacokinetics of the six substrates of the Basel phenotyping cocktail differently. Clin Pharmacokinet. 2022;61(7):1039\u201355.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1261_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.clpt.2006.05.006","volume":"80","author":"RF Frye","year":"2006","unstructured":"Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, et al. Liver disease selectively modulates cytochrome P450\u2013mediated metabolism. Clin Pharmacol Ther. 2006;80(3):235\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1261_CR19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/bcp.14157","volume":"86","author":"C Suenderhauf","year":"2020","unstructured":"Suenderhauf C, Berger B, Puchkov M, Schmid Y, Muller S, Huwyler J, et al. Pharmacokinetics and phenotyping properties of the Basel phenotyping cocktail combination capsule in healthy male adults. Br J Clin Pharmacol. 2020;86(2):352\u201361.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1261_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40262-013-0115-0","volume":"53","author":"M Donzelli","year":"2014","unstructured":"Donzelli M, Derungs A, Serratore MG, Noppen C, Nezic L, Krahenbuhl S, et al. The Basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin Pharmacokinet. 2014;53(3):271\u201382.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1261_CR21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/sj.clpt.6100050","volume":"81","author":"U Fuhr","year":"2007","unstructured":"Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the \u201ccocktail\u201d approach. Clin Pharmacol Ther. 2007;81(2):270\u201383.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1261_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40262-015-0294-y","volume":"55","author":"A Derungs","year":"2016","unstructured":"Derungs A, Donzelli M, Berger B, Noppen C, Kr\u00e4henb\u00fchl S, Haschke M. Effects of cytochrome P450 inhibition and induction on the phenotyping metrics of the Basel cocktail: a randomized crossover study. Clin Pharmacokinet. 2016;55(1):79\u201391.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1261_CR23","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1111\/bcp.14874","volume":"87","author":"F Bachmann","year":"2021","unstructured":"Bachmann F, Duthaler U, Kr\u00e4henb\u00fchl S. Effect of deglucuronidation on the results of the Basel phenotyping cocktail. Br J Clin Pharmacol. 2021;87(12):4608\u201318.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1261_CR24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/hep.1840010617","volume":"1","author":"HO Conn","year":"1981","unstructured":"Conn HO. A peek at the Child-Turcotte classification. Hepatology. 1981;1(6):673\u20136.","journal-title":"Hepatology"},{"issue":"9","key":"1261_CR25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"key":"1261_CR26","first-page":"36","volume":"19","author":"R Preisig","year":"1985","unstructured":"Preisig R. Foreign substances as indicators of liver function. Schweiz Med Wochenschr Suppl. 1985;19:36\u201342.","journal-title":"Schweiz Med Wochenschr Suppl"},{"issue":"3","key":"1261_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/hep.1840140316","volume":"14","author":"J Reichen","year":"1991","unstructured":"Reichen J, Widmer T, Cotting J. Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis: a comparison with the Mayo model. Hepatology. 1991;14(3):504\u201310.","journal-title":"Hepatology"},{"issue":"1","key":"1261_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ijpharm.2016.08.043","volume":"512","author":"M Camblin","year":"2016","unstructured":"Camblin M, Berger B, Haschke M, Krahenbuhl S, Huwyler J, Puchkov M. CombiCap, a novel drug formulation for the Basel phenotyping cocktail. Int J Pharm. 2016;512(1):253\u201361.","journal-title":"Int J Pharm"},{"key":"1261_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-3-642-13443-2_3","volume":"200","author":"MJ Arnaud","year":"2011","unstructured":"Arnaud MJ. Pharmacokinetics and metabolism of natural methylxanthines in animal and man. Handb Exp Pharmacol. 2011;200:33\u201391.","journal-title":"Handb Exp Pharmacol"},{"issue":"6","key":"1261_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3109\/00498254.2011.551849","volume":"41","author":"SK Bae","year":"2011","unstructured":"Bae SK, Jeong YJ, Lee C, Liu KH. Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites. Xenobiotica. 2011;41(6):437\u201344.","journal-title":"Xenobiotica"},{"issue":"9","key":"1261_CR31","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1124\/dmd.109.027706","volume":"37","author":"AS B\u00e9langer","year":"2009","unstructured":"B\u00e9langer AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos. 2009;37(9):1793\u20136.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"1261_CR32","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1124\/dmd.107.015347","volume":"35","author":"Y Mano","year":"2007","unstructured":"Mano Y, Usui T, Kamimura H. Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab Dispos. 2007;35(7):1182\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"1261_CR33","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/00498250310001602739","volume":"33","author":"BK Patel","year":"2003","unstructured":"Patel BK, Jackson SH, Swift CG, Hutt AJ. Disposition of flurbiprofen in man: influence of stereochemistry and age. Xenobiotica. 2003;33(10):1043\u201357.","journal-title":"Xenobiotica"},{"issue":"12","key":"1261_CR34","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147\u201361.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1261_CR35","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1124\/dmd.107.019539","volume":"36","author":"S Klieber","year":"2008","unstructured":"Klieber S, Hugla S, Ngo R, Arabeyre-Fabre C, Meunier V, Sadoun F, et al. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Drug Metab Dispos. 2008;36(5):851\u201362.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1261_CR36","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1124\/dmd.107.017962","volume":"36","author":"B Zhu","year":"2008","unstructured":"Zhu B, Bush D, Doss GA, Vincent S, Franklin RB, Xu S. Characterization of 1\u2032-hydroxymidazolam glucuronidation in human liver microsomes. Drug Metab Dispos. 2008;36(2):331\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"1261_CR37","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1124\/dmd.110.035295","volume":"38","author":"KA Seo","year":"2010","unstructured":"Seo KA, Bae SK, Choi YK, Choi CS, Liu KH, Shin JG. Metabolism of 1\u2032- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab Dispos. 2010;38(11):2007\u201313.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1261_CR38","first-page":"341","volume":"14","author":"KJ Hoffmann","year":"1986","unstructured":"Hoffmann KJ. Identification of the main urinary metabolites of omeprazole after an oral dose to rats and dogs. Drug Metab Dispos. 1986;14(3):341\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1261_CR39","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1046\/j.1365-2125.2001.01389.x","volume":"51","author":"P Marcellin","year":"2001","unstructured":"Marcellin P, de Bony F, Garret C, Altman C, Boige V, Castelnau C, et al. Influence of cirrhosis on lamotrigine pharmacokinetics. Br J Clin Pharmacol. 2001;51(5):410\u20134.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1261_CR40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1208\/s12248-020-00513-5","volume":"22","author":"L Docci","year":"2020","unstructured":"Docci L, Umehara K, Kr\u00e4henb\u00fchl S, Fowler S, Parrott N. Construction and verification of physiologically based pharmacokinetic models for four drugs majorly cleared by glucuronidation: lorazepam, oxazepam, naloxone, and zidovudine. AAPS J. 2020;22(6):128.","journal-title":"AAPS J"},{"issue":"5","key":"1261_CR41","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/j.1742-4658.2007.05670.x","volume":"274","author":"L Barre","year":"2007","unstructured":"Barre L, Fournel-Gigleux S, Finel M, Netter P, Magdalou J, Ouzzine M. Substrate specificity of the human UDP-glucuronosyltransferase UGT2B4 and UGT2B7: identification of a critical aromatic amino acid residue at position 33. FEBS J. 2007;274(5):1256\u201364.","journal-title":"FEBS J"},{"issue":"2","key":"1261_CR42","first-page":"1169","volume":"289","author":"V Furlan","year":"1999","unstructured":"Furlan V, Demirdjian S, Bourdon O, Magdalou J, Taburet AM. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. J Pharmacol Exp Ther. 1999;289(2):1169\u201375.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"1261_CR43","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/clpt.1990.101","volume":"47","author":"AM Taburet","year":"1990","unstructured":"Taburet AM, Naveau S, Zorza G, Colin JN, Delfraissy JF, Chaput JC, et al. Pharmacokinetics of zidovudine in patients with liver cirrhosis. Clin Pharmacol Ther. 1990;47(6):731\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1261_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/BF00614203","volume":"30","author":"H Ghabrial","year":"1986","unstructured":"Ghabrial H, Desmond PV, Watson KJ, Gijsbers AJ, Harman PJ, Breen KJ, et al. The effects of age and chronic liver disease on the elimination of temazepam. Eur J Clin Pharmacol. 1986;30(1):93\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"1261_CR45","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1021\/acs.molpharmaceut.1c00462","volume":"18","author":"E El-Khateeb","year":"2021","unstructured":"El-Khateeb E, Achour B, Al-Majdoub ZM, Barber J, Rostami-Hodjegan A. Non-uniformity of changes in drug-metabolizing enzymes and transporters in liver cirrhosis: implications for drug dosage adjustment. Mol Pharm. 2021;18(9):3563\u201377.","journal-title":"Mol Pharm"},{"issue":"3","key":"1261_CR46","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1124\/dmd.112.048439","volume":"41","author":"RN Hardwick","year":"2013","unstructured":"Hardwick RN, Ferreira DW, More VR, Lake AD, Lu Z, Manautou JE, et al. Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2013;41(3):554\u201361.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1261_CR47","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/hep.1840140626","volume":"14","author":"AJ McCullough","year":"1991","unstructured":"McCullough AJ, Mullen KD, Kalhan SC. Measurements of total body and extracellular water in cirrhotic patients with and without ascites. Hepatology. 1991;14(6):1102\u201311.","journal-title":"Hepatology"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01261-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01261-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01261-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T07:22:16Z","timestamp":1702624936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01261-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1261"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01261-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"assertion":[{"value":"3 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Urs Duthaler, Fabio Bachmann, Agustos C. Ozbey, Kenichi Umehara, Neil Parrott, Stephen Fowler, and Stephan Kr\u00e4henb\u00fchl have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The study was approved by the local ethics committee EKNZ (Ethikkommission Nordwestschweiz\/Zentralschweiz, BASEC-Nr: 2017-01329) and was conducted in accordance with good clinical practice guidelines and the current version of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from every study subject prior to inclusion into the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All subjects signed the informed content which had been explained to them by one of the recruiting study physicians. This is detailed in ref., in which the study is explained in more detail.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Additional data are given in the Electronic Supplementary Material. More data are available on request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Study design: FB, SK. Protocol: FB, SK. Study conduction: FB, SK. Biochemical determinations: UD, FB. Data interpretation: FB, UD, SK. Supervision: UD, SK, NP, SF. Data presentation: FB, UD, SK. Preparation of draft: UD, SK. Preparation of final manuscript version: UD, FB, ACO, KU, NP, SF, SK.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}